title: Regramming myeloid responses to improve cancer immunotherapy.
abstract: Infiltration by immunosuppressive myeloid cells helps tumors to overcome immune surveillance and can render patients less responsive to therapeutic intervention. Several recent studies have demonstrated that reprogramming myeloid responses can effectively enhance cancer immunotherapy, suggesting several new potential combination therapies for clinical testing.
authors.affiliation: Department of Medicine; Washington University School of Medicine ; St. Louis, MO, USA ; Siteman Cancer Center; Washington University School of Medicine ; St. Louis, MO, USA ; ICCE Institute; Washington University School of Medicine ; St. Louis, MO, USA.
authors.forename: Yu
authors.initials: Y
authors.lastname: Zhu
authors.affiliation: Siteman Cancer Center; Washington University School of Medicine ; St. Louis, MO, USA ; Department of Surgery; Washington University School of Medicine ; St. Louis, MO, USA.
authors.forename: William G
authors.initials: WG
authors.lastname: Hawkins
authors.affiliation: Department of Medicine; Washington University School of Medicine ; St. Louis, MO, USA ; Siteman Cancer Center; Washington University School of Medicine ; St. Louis, MO, USA ; ICCE Institute; Washington University School of Medicine ; St. Louis, MO, USA ; Department of Pathology and Immunology; Washington University School of Medicine ; St. Louis, MO, USA.
authors.forename: David G
authors.initials: DG
authors.lastname: DeNardo
keywords: MDSCs; PD-1; cancer immunotherapy; immune checkpoints; macrophages